Maryland Settles EpiPen Claims Against Mylan, Inc.
June 29, 2026
On May 4, 2026, Maryland’s Attorney General announced that the Antitrust Division reached a settlement with Mylan Inc. (Mylan), the company that sells the EpiPen®, resolving concerns about anticompetitive conduct involving the cost, marketing, and availability of EpiPen products. The Ep[...]
Continue Reading
Safety Label Update For Capecitabine And Fluorouracil (5-FU)
March 28, 2026
The U.S. Food and Drug Administration (FDA) recently provided a communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency: all healthcare providers s[...]
Continue Reading
FDA Warns Companies Over Illegal Marketing Of Botox
February 14, 2026
In November 2025, the U.S. Food and Drug Administration issued 18 warning letters to owners of websites illegally marketing unapproved and misbranded botulinum toxin products, commonly called Botox. The FDA is aware of adverse events associated with unapproved and misbranded botulinum toxin products[...]
Continue Reading